fluoxetine has been researched along with Asthenia in 2 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Asthenia: Clinical sign or symptom manifested as debility, or lack or loss of strength and energy.
| Excerpt | Relevance | Reference |
|---|---|---|
| " To assess rates and temporal patterns of activation and sedation as well as dose-effect relationships, adverse event data were evaluated from a fixed-dose study comparing placebo and fluoxetine 5, 20, and 40 mg/day in the treatment of major depressive disorder (N = 363) and two fixed-dose studies pooled together comparing placebo and fluoxetine 20, 40, and 60 mg/day in the treatment of major depressive disorder (N = 746)." | 5.07 | Fluoxetine: activating and sedating effects at multiple fixed doses. ( Beasley, CM; Potvin, JH; Sayler, ME; Weiss, AM, 1992) |
| " The purpose of this study was to assess the potential for pharmacokinetic interaction between olanzapine and fluoxetine, a popular antidepressant that is a selective serotonin reuptake inhibitor." | 2.70 | Influence of fluoxetine on olanzapine pharmacokinetics. ( de Suray, JM; Gangji, D; Gossen, D; Onkelinx, C; Vandenhende, F, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gossen, D | 1 |
| de Suray, JM | 1 |
| Vandenhende, F | 1 |
| Onkelinx, C | 1 |
| Gangji, D | 1 |
| Beasley, CM | 1 |
| Sayler, ME | 1 |
| Weiss, AM | 1 |
| Potvin, JH | 1 |
2 trials available for fluoxetine and Asthenia
| Article | Year |
|---|---|
Influence of fluoxetine on olanzapine pharmacokinetics.
Topics: Adult; Antipsychotic Agents; Asthenia; Benzodiazepines; Cross-Over Studies; Depressive Disorder; Dru | 2002 |
Fluoxetine: activating and sedating effects at multiple fixed doses.
Topics: Adult; Akathisia, Drug-Induced; Ambulatory Care; Anxiety; Asthenia; Depressive Disorder; Dose-Respon | 1992 |